Osteoporosis caused by Glucocorticoid Treatment

Also known as: Glucocorticoid Induced Osteoporosis / Steroid-induced osteoporosis / Osteoporosis, Steroid Induced / Osteoporosis caused by glucocorticoid / Osteoporosis caused by corticosteroid / Osteoporosis steroid-induced / Glucocorticoid-induced Osteoporosis / Osteoporosis caused by corticosteroid (disorder) / Osteoporosis due to corticosteroids (disorder) / Osteoporosis / Osteoporosis (disorder) / Osteoporosis NOS (disorder) / Involutional osteoporosis without current pathological fracture / Osteoporosis, unspecified / Osteoporosis NOS / Osteoporosis, unspecified (disorder)

DrugDrug NameDrug Description
DB00630Alendronic acidA bisphosphonate drug that prevents osteoclastic bone resorption which is used for the prevention and treatment of osteoporosis.
DB06643DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
DB13169NandroloneAn anabolic steroid indicated to increase bone density and muscle mass in patients with osteoporosis.
DB00481RaloxifeneA selective estrogen receptor modulator that is used to prevent and treat osteoporosis and reduce the risk of invasive breast cancer in high-risk postmenopausal women.
DB06285TeriparatideA recombinant parathyroid hormone used for the treatment of osteoporosis.
DB00399Zoledronic acidA bisphosphonate used to treat malignancy associated hypercalcemia, multiple myeloma, and bone metastasis from solid tumors.
DrugDrug NameTargetType
DB00630Alendronic acidFarnesyl pyrophosphate synthasetarget
DB00630Alendronic acidTyrosine-protein phosphatase non-receptor type 4target
DB00630Alendronic acidReceptor-type tyrosine-protein phosphatase Starget
DB00630Alendronic acidReceptor-type tyrosine-protein phosphatase epsilontarget
DB00630Alendronic acidV-type proton ATPase catalytic subunit Atarget
DB00630Alendronic acidHydroxylapatitetarget
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB00481RaloxifeneEstrogen receptor alphatarget
DB00481RaloxifeneEstrogen receptor betatarget
DB00481RaloxifeneAldehyde oxidaseenzyme
DB00481RaloxifeneCytochrome P450 2C8enzyme
DB00481RaloxifeneCytochrome P450 2B6enzyme
DB00481RaloxifeneCytochrome P450 19A1enzyme
DB00481RaloxifeneCytochrome P450 3A4enzyme
DB00481RaloxifeneSerpin B9target
DB00481RaloxifeneTrefoil factor 1target
DB00481RaloxifeneUDP-glucuronosyltransferase 1-1enzyme
DB00481RaloxifeneSerum albumincarrier
DB00481RaloxifeneAlpha-1-acid glycoprotein 1carrier
DB00481RaloxifeneSolute carrier organic anion transporter family member 1B1transporter
DB00481RaloxifeneSolute carrier organic anion transporter family member 1B3transporter
DB00481RaloxifeneP-glycoprotein 1transporter
DB00481RaloxifeneATP-binding cassette sub-family G member 2transporter
DB00481RaloxifeneCanalicular multispecific organic anion transporter 1transporter
DB00481RaloxifeneCanalicular multispecific organic anion transporter 2transporter
DB00481RaloxifeneMultidrug resistance-associated protein 4transporter
DB00481RaloxifeneUDP-glucuronosyltransferase 1-10enzyme
DB00481RaloxifeneUDP-glucuronosyltransferase 1-8enzyme
DB06285TeriparatideParathyroid hormone/parathyroid hormone-related peptide receptortarget
DB00399Zoledronic acidFarnesyl pyrophosphate synthasetarget
DB00399Zoledronic acidGeranylgeranyl pyrophosphate synthasetarget
DB00399Zoledronic acidHydroxylapatitetarget
DB00399Zoledronic acidMultidrug resistance-associated protein 1transporter
DrugDrug NamePhaseStatusCount
DB06643Denosumab1 / 2Withdrawn1
DB00630Alendronic acid2Not Yet Recruiting1
DB19002Narlumosbart2Not Yet Recruiting1
DB00630Alendronic acid2 / 3Unknown Status1
DB06643Denosumab3Completed1
DB11866Romosozumab4Completed1
DB06285TeriparatideNot AvailableCompleted1